Progressive Supranuclear Palsy (PSP) is a rare but devastating neurodegenerative disorder characterized by progressive postural instability, vertical gaze palsy, parkinsonism, and cognitive decline. While PSP was once considered a "sporadic" disease, increasing evidence suggests that epigenetic alterations play a significant role in its pathogenesis 1. Epigenetic changes—heritable modifications to DNA and chromatin that regulate gene expression without altering the DNA sequence—have emerged as key contributors to neurodegeneration in PSP and related tauopathies.
Epigenetic dysregulation in PSP affects multiple molecular pathways, including those involved in tau protein metabolism, neuroinflammation, mitochondrial function, and neuronal survival. Understanding these epigenetic changes provides insights into disease mechanisms and potential therapeutic targets 2.
[^3]
[^4]
[^5]
[^6]
[^7]
[^8]
| Mechanism Name | Epigenetic Changes in PSP |
|---|
| Category | Molecular Pathology |
|---|
| Related Diseases | Progressive Supranuclear Palsy |
|---|
| Key Processes | DNA methylation, histone modifications, non-coding RNAs |
|---|
[^9]
[^10]
One of the most prominent epigenetic changes in PSP is global DNA hypomethylation 3. This reduction in methylated cytosine residues across the genome leads to:
- Activation of transposable elements: Normally silenced by methylation, transposons become active and can cause genomic instability
- Altered gene expression: Both increased expression of normally silenced genes and dysregulation of tissue-specific genes
- Chromatin relaxation: Reduced methylation promotes an open chromatin configuration
Detailed studies have identified specific genes with altered methylation patterns in PSP brain tissue:
Tau-related genes:
- Altered methylation of microtubule-associated protein tau (MAPT) gene regulatory regions
- Changes in methylation of kinases that phosphorylate tau
- Methylation changes in tau-related transcription factors
Inflammatory genes:
- Dysregulated methylation of cytokine genes
- Altered patterns in immune response regulators
- Changes in glial cell-specific gene expression
Neuroprotective genes:
- Reduced methylation of antioxidant enzyme genes
- Altered methylation of pro-survival factor promoters
- Changes in DNA repair gene methylation
Several factors contribute to DNA methylation alterations in PSP:
- DNA methyltransferase (DNMT) dysfunction: Altered activity or expression of DNMTs
- S-adenosylmethionine (SAM) depletion: Reduced methyl donor availability
- Tert (telomerase reverse transcriptase) changes: Altered TERT expression affects methylation patterns
- Environmental factors: Potential influence of lifetime exposures
Changes in histone acetylation patterns are observed in PSP 4:
Reduced histone acetylation:
- Decreased H3 and H4 acetylation levels
- Associated with transcriptional repression
- Linked to reduced cognitive function
Histone deacetylase (HDAC) alterations:
- Increased HDAC activity in PSP brain
- HDAC2 overexpression in affected regions
- Therapeutic potential of HDAC inhibitors
Altered histone methylation patterns contribute to PSP pathogenesis:
H3K4me3 (activating mark):
- Reduced levels in PSP prefrontal cortex
- Associated with transcriptional downregulation
H3K27me3 (repressive mark):
- Altered distribution in PSP
- Affects development and differentiation genes
H3K9me3 (constitutive heterochromatin):
- Changes in heterochromatin stability
- Genomic instability implications
Stress-activated kinases that phosphorylate histones are dysregulated in PSP:
- p38 MAPK activation leads to H3 phosphorylation
- JNK activation affects histone modifications
- Links between stress response and epigenetic changes
Multiple miRNAs are dysregulated in PSP 5:
Upregulated miRNAs:
- miR-124: Altered neuronal plasticity
- miR-128: Affects tau phosphorylation
- miR-219: Dysregulated in glia
Downregulated miRNAs:
- miR-7: Reduced in PSP brain
- miR-153: Targets tau kinase genes
- miR-132: Altered in PSP
Emerging evidence suggests lncRNA involvement in PSP:
- NEAT1: Altered nuclear organization
- MALAT1: Splicing regulation changes
- HOTAIR: Affects developmental genes
The role of circRNAs in PSP is beginning to be explored:
- Altered circRNA expression patterns
- Potential as biomarkers
- Regulatory functions in neuronal homeostasis
¶ Tau Protein and Epigenetics
The MAPT gene shows altered methylation in PSP:
- Differential methylation of MAPT promoter affects expression
- H1 haplotype influence on methylation patterns
- Links between genetic background and epigenetic changes
¶ Tau Acetylation and Degradation
Epigenetic mechanisms affect tau protein metabolism:
- Acetylation affects tau degradation
- HDAC6 regulation of tau acetylation
- Acetylation-mimicking mutations and pathology
Epigenetic changes may facilitate tau propagation:
- Cell-to-cell transmission mechanisms
- Role of extracellular vesicles
- Epigenetic reprogramming in recipient cells
¶ Neuroinflammation and Epigenetics
Epigenetic changes in microglia and astrocytes 6:
- Altered cytokine gene methylation
- Changes in glial activation patterns
- NF-κB pathway epigenetic dysregulation
Systemic immune changes in PSP:
- Altered immune cell methylation patterns
- Potential peripheral biomarkers
- Inflammatory epigenetic signatures
¶ Mitochondrial Dysfunction and Epigenetics
Mitochondrial genome shows epigenetic changes:
- Altered mtDNA methylation
- Correlations with mitochondrial dysfunction
- Implications for energy metabolism
Epigenetic mechanisms affecting mitochondria:
- PGC-1α methylation changes
- Mitochondrial biogenesis dysregulation
- Metabolic consequences
Potential treatment strategies targeting epigenetic changes 7:
HDAC inhibitors:
- Vorinostat, Valproic acid
- Suberoylanilide hydroxamic acid (SAHA)
- Testing in tauopathy models
DNMT inhibitors:
- 5-azacytidine
- Decitabine
- Limited CNS penetration challenges
BET inhibitors:
- JQ1, I-BET762
- Target bromodomain proteins
- Emerging therapeutic potential
¶ Lifestyle and Environmental Factors
Modifiable factors that may influence epigenetic changes:
- Diet and nutrition
- Exercise
- Cognitive stimulation
- Stress management
Epigenetic changes have biomarker potential in PSP:
- Peripheral blood mononuclear cell methylation
- miRNA signatures in CSF
- Exosomal epigenetic marks
¶ Diagnostic and Prognostic Value
- Early detection potential
- Disease progression markers
- Treatment response monitoring
Epigenetic changes are studied using:
- Bisulfite sequencing: DNA methylation analysis
- ChIP-seq: Histone modification mapping
- RNA-seq: Non-coding RNA profiling
- ATAC-seq: Chromatin accessibility
Research relies on:
- Postmortem brain tissue
- Animal models of tauopathy
- Induced pluripotent stem cells (iPSCs)
- Cell culture models
Epigenetic alterations represent a fundamental aspect of PSP pathogenesis, contributing to disease progression through multiple interconnected mechanisms. The complex interplay between genetic susceptibility and epigenetic dysregulation provides insights into the heterogeneity of PSP presentations and the challenges of developing effective therapies. While targeting epigenetic mechanisms offers therapeutic promise, the complexity of the epigenetic landscape and the need for brain-penetrant drugs present significant challenges. Future research focusing on understanding the causal relationships between epigenetic changes and neurodegeneration, developing selective epigenetic modulators, and identifying reliable biomarkers will be essential for translating these findings into clinical benefits.